The natural history of Parkinson's disease in the province of Segovia: mortality in a longitudinal study (20-year follow-up)
Version of Record online: 7 SEP 2012
© 2012 John Wiley & Sons A/S
Acta Neurologica Scandinavica
Volume 127, Issue 5, pages 295–300, May 2013
How to Cite
The natural history of Parkinson's disease in the province of Segovia: mortality in a longitudinal study (20-year follow-up). Acta Neurol Scand: DOI: 10.1111/ane.12003. © 2012 John Wiley & Sons A/S., , , .
- Issue online: 13 APR 2013
- Version of Record online: 7 SEP 2012
- Manuscript Accepted: 31 JUL 2012
- natural history;
- Parkinson's disease
We determined mortality rates and predictors of survival in 273 patients with Parkinson's disease based on a 20-year follow-up longitudinal study.
Material and methods
We examined 273 patients with Parkinson's disease during a 20-year follow-up, recruited between 1978 and 1998. All patients were regularly followed at the Department of Neurology until December 31, 1998, or death.
By then, 69 patients had died, crude mortality was rate 4.43, and standardized mortality ratio for the total patient group was 1.39 (95% CI, 1.10–1.50). As Parkinson's disease is a chronic progressive disorder in adult life, disease-related mortality would be expected to increase in later stages after 15 or 20 years. Mean age at death in our cohort was 78.27 (95% CI, 76.90–79.20). Median time of death was 11 years (95% CI, 9.50–12.49). Independent predictors of mortality during the follow-up were age at onset (hazard ratio, 1.05; 95% CI, 1.01–1.09; P = 0.01), clinical form – akinesia and rigidity (hazard ratio, 2.20; 95% CI, 1.06–4.88; P = 0.03) – and treatment with dopaminergic agonist (hazard ratio, 0.49; 95% CI, 0.23–1.03; P = 0.06). Cardiovascular disease was the most frequent cause of death in 42%.
This study suggests a link between mortality with age of onset and treatment without dopamine agonists as initial treatment. So, there is an association between decreased mortality and tremor as initial clinical forms at onset.